Cell Medica is actively seeking licensing and partnering opportunities, drawing on global immunotherapy expertise, to explore and advance the therapeutic possibilities for our T cell immunotherapy products.
To learn more about our partnering opportunities please contact our Business Development team at: email@example.com
Alongside world-class research institutions and industry leaders, we are developing next-generation cellular therapies to transform cancer treatment.
Cell Medica and the Centre for Cell and Gene Therapy (CAGT) at Baylor College of Medicine have an ongoing R&D partnership that also includes University of North Carolina (UNC), signed in April 2016. Baylor is a world class centre with significant expertise in cell and gene therapy across basic research, translational and clinical trials.
Our collaboration focuses on the development of our CAR-NKT platform through pre-clinical and clinical development. The team, led by Prof Leonid Metelitsa and Dr Andras Heczey, are working to advance the pioneering CAR-NKT platform, a first-in-class innovative CAR T cell therapy.
Cell Medica has exclusive rights to the CAR-NKT Intellectual Property (IP) generated at Baylor.
Cell Medica and the team at the Institute of Immunity and Transplantation, UCL, have been working closely since July 2016 to develop our T cell Receptor (TCR) pipeline. The Dominant TCR technology resulted from the work of Profs Hans Stauss and Emma Morris.
Together, we are collaborating with the Royal Free Hospital NHS Trust to continue the research and deliver these novel therapies to patients in the clinic.
Cell Medica has exclusive rights to the Dominant TCR IP generated at UCL.
Cell Medica and the Cell & Gene Therapy Catapult (CGT Catapult) have a multi-dimensional partnership for the commercial development of our CAR-NKT and TCR pipeline. The CGT Catapult are a global, manufacturing and R&D innovation centre of excellence for advanced cell therapies.
Since March 2018 Cell Medica have been in their newly opened, state of the art, specialised cell & gene therapy manufacturing facility in Stevenage, UK. In addition, some or our TCR pipeline originated from a CGT Catapult, UCL and Imperial College collaboration. Together, we are guiding the technology through pre-clinical and clinical development.